CryoLife Reports First Quarter 2016 Financial Results
ATLANTA, April 27, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today its results for the first quarter of 2016.
Recent Highlights:
- First Quarter Revenue Increased 27 Percent Year-over-Year to $43.0 Million; Pro Forma Revenues Increased Nine Percent Year-over-Year
- Strengthened Focus on Cardiac Surgery Technologies and Enhanced Growth Potential Through Strategic Initiatives, including:
- Acquisition of On-X® Life Technologies (On-X)
- Sale of HeRO® Graft Product Line
- Sale of ProCol® Distribution Rights and Purchase Option
- Purchase of PhotoFix™ Product Line
- First Quarter Adjusted Non-GAAP Net Income was $3.2 Million, or $0.10 Per Fully Diluted Common share; GAAP Net Income for the First Quarter was $2.5 Million, or $0.08 Per Fully Diluted Common Share
J. Patrick Mackin, Chairman, President and Chief Executive Officer, said, "In the first three months of 2016, we completed several transactions that we expect will enhance our revenue growth, drive margin expansion and strengthen our presence in the cardiac surgery market. Our outlook is based primarily on the opportunity presented by the On-X acquisition. With that transaction, we now have access to the mechanical heart valve market, which we estimate to be $220 million annually. On-X is a best in class mechanical heart valve technology, backed by powerful clinical data. The acquisition more than doubled our U.S. cardiac surgery sales force. Although it is early, the On-X integration is going very well and we are very encouraged by our initial experiences with the product and the results being obtained by our combined sales team. We further strengthened our focus in cardiac surgery with the sale of the HeRO Graft product line and ProCol distribution rights and purchase option, as well as the exercise this month of our purchase option for the PhotoFix product line. Our combined sales team is now able to devote its full attention on a select portfolio of highly competitive cardiac surgery products with similar call points. We will continue to build on the momentum from the first quarter and we believe we can deliver meaningful progress on all of our strategic initiatives for 2016."
Revenues for the first quarter of 2016 increased 27 percent to $43.0 million, compared to $33.8 million for the first quarter of 2015. The increase was primarily driven by the acquisition of On-X, and revenue increases in vascular tissues and BioGlue®. Pro forma revenues for the first quarter of 2016 increased nine percent compared to the first quarter of 2015. A reconciliation of revenues to pro forma revenues is included in the schedules below.
Adjusted non-GAAP net income for the first quarter of 2016 was $3.2 million, or $0.10 per fully diluted common share, compared to adjusted non-GAAP net income of $230,000, or $0.01 per fully diluted common share for the first quarter of 2015. GAAP net income for the first quarter of 2016 was $2.5 million, or $0.08 per basic and fully diluted common share, compared to net loss of ($274,000), or ($0.01) per basic and fully diluted common share, for the first quarter of 2015. A reconciliation of GAAP to non-GAAP earnings is included in the schedules below.
The Company is reiterating its 2016 financial guidance as summarized below.
| 2016 Financial Guidance Summary |
|
| Total revenues |
$178 million - $180 million Mid-single digits % pro-forma increase over 2016 |
| Product revenues |
Mid-single digits % pro-forma increase over 2016 |
| Tissue processing revenues |
Mid-single digits % increase over 2016 |
| Gross margins |
Approximately 63% |
| R&D expenses |
$13.0 million - $15.0 million |
| Non-GAAP adjusted income per common share |
$0.29 - $0.32 |
The Company's financial guidance for the full year of 2016 is subject to the risks identified below in the last paragraph of this press release before the financial tables. The guidance does not include any effect related to future business development activities and other unusual charges.
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with U.S. GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. Non-GAAP adjusted net income and adjusted income per common share excludes business development expenses, including the acquired inventory basis step-up; gain on sale of business components; amortization expenses; severance expenses associated with certain employee departures; the write-off of PerClot Topical inventory; and intangible impairment. Non-GAAP revenues include On-X revenues for the period in 2016 prior to the acquisition and On-X revenues for the first quarter of 2015 and excludes revenues for the HeRO Graft and ProCol for the first quarters of 2016 and 2015. Non-GAAP gross margin excludes the acquisition inventory basis step-up expense. Non-GAAP general, administrative, and marketing excludes business development expenses. The Company believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions and the operating expense structure of the Company's existing and recently acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses and the transaction and integration expenses incurred in connection with recently acquired and divested product lines. The Company believes it is useful to exclude certain expenses because such amounts in any specific period may not directly correlate to the underlying performance of our business operations and can vary significantly between periods as a result of factors such as new acquisitions, amortization of previously acquired tangible and intangible assets, or unusual compensation expenses. The Company does, however, expect to incur similar types of expenses in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur.
Webcast and Conference Call Information
The Company will hold a teleconference call and live webcast tomorrow at 8:00 a.m. Eastern Time to discuss the results followed by a question and answer session hosted by Mr. Mackin.
To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 8:00 a.m. A replay of the teleconference will be available April 28 through May 5 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13634919.
The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife website at www.cryolife.com and selecting the heading Webcasts & Presentations.
About CryoLife, Inc.
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of implantable living tissues and medical devices used in cardiac surgical procedures. CryoLife markets and sells products in more than 80 countries worldwide. For additional information about CryoLife, visit our website, www.cryolife.com.
Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include those regarding CryoLife's expectations that the On-X acquisition and other transactions we consummated in the first quarter of 2016 will enhance our revenue growth, drive margin expansion, and strengthen our presence in the cardiac surgery market; CryoLife's On-X based outlook; the size of the annual addressable mechanical heart valve market; the success of our On-X integration; the results being obtained by our sales team including the On-X sales team; our expectation and belief that our combined sales team is now able to devote its full attention on a select portfolio of highly competitive cardiac surgery products with similar call points; the expectation that we will continue to build on the momentum from the first quarter; and the statement that we can deliver meaningful progress on all of our strategic initiatives for 2016. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. These risks and uncertainties include that the expected market opportunities for mechanical heart valves may be incorrect and/or may shrink due to factors beyond our control; and the expected benefits of focusing market opportunities may be incorrect. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2015, and our subsequent filings with the SEC. CryoLife does not undertake to update its forward-looking statements.
| CRYOLIFE, INC. AND SUBSIDIARIES |
||||||
| Financial Highlights |
||||||
| (In thousands, except per share data) |
||||||
| Three Months Ended |
||||||
| March 31, |
||||||
| 2016 |
2015 |
|||||
| Revenues: |
||||||
| Products |
$ |
27,018 |
$ |
19,391 |
||
| Preservation services |
15,998 |
14,440 |
||||
| Total revenues |
43,016 |
33,831 |
||||
| Cost of products and preservation services: |
||||||
| Products |
7,003 |
5,033 |
||||
| Preservation services |
8,392 |
9,131 |
||||
| Total cost of products and preservation services |
15,395 |
14,164 |
||||
| Gross margin |
27,621 |
19,667 |
||||
| Operating expenses: |
||||||
| General, administrative, and marketing |
26,274 |
18,969 |
||||
| Research and development |
2,609 |
2,252 |
||||
| Total operating expenses |
28,883 |
21,221 |
||||
|
Gain on sale of business components |
7,915 |
- |
||||
|
Operating income (loss) |
6,653 |
(1,554) |
||||
| Interest expense |
717 |
30 |
||||
| Interest income |
(12) |
(3) |
||||
| Other (income) expense, net |
(109) |
192 |
||||
|
Income (loss) before income taxes |
6,057 |
(1,773) |
||||
| Income tax expense (benefit) |
3,516 |
(1,499) |
||||
| Net income (loss) |
$ |
2,541 |
$ |
(274) |
||
| Income (loss) per common share: |
||||||
| Basic |
$ |
0.08 |
$ |
(0.01) |
||
| Diluted |
$ |
0.08 |
$ |
(0.01) |
||
| Dividends declared per common share |
$ |
- |
$ |
0.03 |
||
| Weighted-average common shares outstanding: |
||||||
| Basic |
31,029 |
27,523 |
||||
| Diluted |
31,771 |
27,523 |
||||
| CRYOLIFE, INC. AND SUBSIDIARIES |
||||||||
| Financial Highlights |
||||||||
| (In thousands) |
||||||||
| Three Months Ended |
||||||||
| March 31, |
||||||||
| 2016 |
2015 |
|||||||
| Products: |
||||||||
| BioGlue and BioFoam |
$ |
15,316 |
$ |
14,042 |
||||
| On-X |
6,715 |
- |
||||||
| CardioGenesis cardiac laser therapy |
1,984 |
2,137 |
||||||
| PerClot |
991 |
976 |
||||||
| PhotoFix |
381 |
172 |
||||||
| HeRO Graft |
1,413 |
1,860 |
||||||
| ProCol |
218 |
204 |
||||||
| Total Products |
27,018 |
19,391 |
||||||
| Preservation services: |
||||||||
| Cardiac tissue |
6,428 |
6,663 |
||||||
| Vascular tissue |
9,570 |
7,777 |
||||||
| Total preservation services |
15,998 |
14,440 |
||||||
| Total revenues |
$ |
43,016 |
$ |
33,831 |
||||
| Revenues: |
||||||||
| U.S. |
$ |
32,238 |
$ |
27,034 |
||||
| International |
10,778 |
6,797 |
||||||
| Total revenues |
$ |
43,016 |
$ |
33,831 |
||||
| March 31, |
December 31, |
||||
| 2016 |
2015 |
||||
| Cash, cash equivalents, and restricted cash and securities |
$ |
45,639 |
$ |
43,418 |
|
| Total current assets |
129,236 |
109,663 |
|||
| Total assets |
297,157 |
181,179 |
|||
| Total current liabilities |
24,842 |
19,605 |
|||
| Total liabilities |
102,997 |
25,928 |
|||
| Shareholders' equity |
194,160 |
155,251 |
|||
| CRYOLIFE, INC. AND SUBSIDIARIES |
||||||
| Reconciliation of GAAP to Non-GAAP |
||||||
| Net Income and Diluted Income Per Common Share |
||||||
| (In thousands, except per share data) |
||||||
| Three Months Ended |
||||||
| March 31, |
||||||
| 2016 |
2015 |
|||||
| GAAP: |
||||||
| Income (loss) before income taxes |
$ |
6,057 |
$ |
(1,773) |
||
| Income tax expense (benefit) |
3,516 |
(1,499) |
||||
| Net Income (loss) |
$ |
2,541 |
$ |
(274) |
||
| Diluted income (loss) per common share: |
$ |
0.08 |
$ |
(0.01) |
||
| Reconciliation of income (loss) before income taxes, |
||||||
| GAAP to adjusted net income (loss), non-GAAP: |
||||||
| Income (loss) before income taxes, GAAP |
$ |
6,057 |
$ |
(1,773) |
||
| Adjustments: |
||||||
| Business development expenses |
5,568 |
206 |
||||
| Gain on sale of business components |
(7,915) |
-- |
||||
| Amortization expense |
962 |
515 |
||||
| Acquisition inventory basis step-up expense |
565 |
-- |
||||
| Severance expenses |
-- |
468 |
||||
| Write-off of PerClot Topical inventory |
-- |
498 |
||||
| Intangible impairment |
-- |
457 |
||||
| Adjusted income before income taxes, |
||||||
| non-GAAP |
5,237 |
371 |
||||
| Income tax expense calculated at a |
||||||
| pro forma tax rate of 38% |
1,990 |
141 |
||||
| Adjusted net income, non-GAAP |
$ |
3,247 |
$ |
230 |
||
| Reconciliation of diluted income (loss) per common |
||||||
| share, GAAP to adjusted diluted income (loss) per |
||||||
| common share, non-GAAP: |
||||||
| Diluted income (loss) per common share – GAAP |
$ |
0.08 |
$ |
(0.01) |
||
| Adjustments net of 38% tax rate: |
||||||
| Business development expenses |
0.11 |
0.01 |
||||
| Gain on sale of business components |
(0.16) |
-- |
||||
| Amortization expense |
0.02 |
0.01 |
||||
| Acquisition inventory basis step-up expense |
0.01 |
-- |
||||
| Severance expenses |
-- |
0.01 |
||||
| Write-off of PerClot Topical inventory |
-- |
0.01 |
||||
| Intangible impairment |
-- |
0.01 |
||||
| Effect of 38% pro forma tax rate on GAAP pretax book income |
0.04 |
(0.03) |
||||
| Adjusted diluted income per common share, |
||||||
| non-GAAP: |
$ |
0.10 |
$ |
0.01 |
||
| Diluted-weighted average common |
||||||
| shares outstanding: |
31,771 |
28,426 |
||||
| CRYOLIFE, INC. AND SUBSIDIARIES |
||||||||
| Reconciliation of GAAP to Non-GAAP |
||||||||
| Revenues; Gross Margin; General, Administrative, and Marketing |
||||||||
| (In thousands, except per share data) |
||||||||
| Three Months Ended |
||||||||
| March 31, |
||||||||
| 2016 |
2015 |
Growth |
||||||
| Reconciliation of total revenues, GAAP to |
||||||||
| Total revenues, GAAP |
$ |
43,016 |
$ |
33,831 |
27% |
|||
| Plus: On-X pre acquisition revenues |
1,627 |
7,781 |
||||||
| Less: HeRO revenues |
(1,413) |
(1,860) |
||||||
| Less: ProCol revenues |
(218) |
(204) |
||||||
| Total revenues, non-GAAP |
$ |
43,012 |
$ |
39,548 |
9% |
|||
| Three Months Ended |
||||||||
| March 31, 2016 |
||||||||
| Reconciliation of gross margin %, GAAP to |
||||||||
| Total revenues, GAAP |
$ |
43,016 |
||||||
| Gross margin, GAAP |
$ |
27,621 |
||||||
| Gross margin %, GAAP |
64% |
|||||||
| Gross margin, GAAP |
$ |
27,621 |
||||||
| Plus: Acquisition inventory basis step-up expense |
565 |
|||||||
| Gross margin, non-GAAP |
$ |
28,186 |
||||||
| Gross margin %, non-GAAP |
66% |
|||||||
| Three Months Ended |
||||||||
| March 31, 2016 |
||||||||
| Reconciliation of general, administrative, and marketing, GAAP |
||||||||
| General, administrative, and marketing, GAAP |
$ |
26,274 |
||||||
| Less: Business development expenses |
(5,568) |
|||||||
| General, administrative, and marketing, non-GAAP |
$ |
20,706 |
||||||
| Contacts: |
|
| CryoLife |
The Ruth Group |
| D. Ashley Lee |
Nick Laudico / Zack Kubow |
| Executive Vice President, Chief Financial Officer |
646-536-7030 / 7020 |
| and Chief Operating Officer |
|
| Phone: 770-419-3355 |
Logo - http://photos.prnewswire.com/prnh/20140319/MM86518LOGO
SOURCE CryoLife, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article